China Drafts 2025 Risk Management Plan for Innovative Drug R&D

China has released a draft guideline for public consultation outlining risk management requirements during the R&D phase of innovative drugs. Once implemented, this guideline will establish a systematic framework for Risk Management Plan (RMP) preparation applicable to clinical development of chemical drugs, biologics, and traditional Chinese medicines. The proposed regulation is designed to align China’s drug development quality systems with international standards, which may affect global regulatory strategies for companies seeking China market entry.

The development of this guideline supports the implementing the concept of whole-life-cycle drug regulation. By requiring the early establishment of a comprehensive Risk Management Plan (RMP) during R&D, it will help companies systematically identify, assess, and control potential risks, thereby reducing safety hazards in clinical trials and improving R&D success rates.

Key Content Interpretation

Scope Clarification

The guideline applies to clinical R&D stages of innovative chemical drugs, biologics, and traditional Chinese medicines. It emphasizes heightened scrutiny for high-risk products, including but not limited to cutting-edge therapies such as gene therapy, cell therapy, and tumor immunotherapy. Companies in these fields will need to allocate additional resources to meet the new regulatory requirements.

Risk Management Plan (RMP) Framework Requirements

Risk Identification: Requires comprehensive identification of potential safety risks (e.g., toxicity, off-target effects, immunogenicity) based on non-clinical data and early clinical trial results.
Risk Assessment: Mandates scientific evaluation of identified risks to determine severity levels and identify "critical risks" requiring prioritized monitoring.
Risk Control Measures: Requires tailored strategies for different risk levels, such as dose adjustment protocols, special population monitoring plans, and risk minimization measures.
Pharmacovigilance Plan: Details procedures for adverse event collection, evaluation, and reporting to ensure timely safety information communication.

Dynamic Update Mechanism

The guideline emphasizes that RMPs should be "living documents," requiring continuous updates based on R&D progress. Companies must establish internal processes to promptly integrate new safety data and adjust risk management strategies.

Industry Impact Analysis

Higher R&D Management Requirements: The new rules will increase management requirements for innovative drug R&D. Companies must establish dedicated risk management teams or engage professional CROs to meet regulatory requirements, potentially increasing R&D costs. Small and medium-sized enterprises (SMEs) may face greater resource pressures.
Accelerated Global Integration: Compliance with international-standard risk management systems Chinese-developed products will facilitate the overseas expansion of Chinese innovative drugs. As the EU EMA and U.S. FDA already require detailed RMPs, domestic companies adhering to high standards now will reduce future compliance hurdles for international submissions.
Optimized Resource Allocation: Early identification of high-risk projects will enable companies to allocate R&D resources more efficiently, avoiding substantial losses due to late-stage safety issues. Long-term benefits include improved industry-wide R&D efficiency.

Key Controversies and Recommendations

During the public consultation, industry stakeholders raised the following concerns according to sources:

Balance Between Flexibility and Standardization: Some companies worry that overly prescriptive rules may stifle innovation.
Recommendation: Maintain a unified framework while allowing flexibility for drugs with distinct risk profiles.
Burden on SMEs: SMEs with limited resources may struggle to fully comply.
Recommendation: Regulatory authorities should provide supportive measures (e.g., template documents, training programs) to reduce compliance costs.
Alignment with Existing Documents: Clarification is needed on how RMPs interact with current documents like the Investigator’s Brochure (IB) and clinical trial protocols to avoid redundant efforts.
Implementation Transition Period:
Recommendation: Introduce a phased rollout, starting with mandatory enforcement for high-risk drugs before expanding to all innovative drugs.

The development of the Technical Guideline for Risk Management Plan Preparation During Innovative Drug R&D will increase compliance costs for Chinese drug manufacturers but is intended to enhance the overall quality of China’s innovative drug R&D and promote high-quality development in the pharmaceutical industry.

Further Information

To read the original announcement about the draft guideline on Risk Management Plan Preparation During Innovative Drug R&D released for public consultation, please click here.

If you are a pharmaceutical company with questions about how China’s new risk management guideline may affect your clinical development plans or submissions, please contact Cisema.